Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Kanjinti“
Suchtreffer
Begriffe & Kennungen
Kanjinti · 4.8 · 12 System organ class Adverse reaction Frequency + Acute pulmonary oedema Not known + Acute respiratory distre
Eintrag öffnenKanjinti · 4.8 · 13 System organ class Adverse reaction Frequency Pregnancy, puerperium and Oligohydramnios Not known perinatal
Eintrag öffnenKanjinti · 4.8 · 14 seen in patients receiving trastuzumab concurrently with anthracycline/cyclophosphamide (27%), and was sign
Eintrag öffnenKanjinti · 4.8 · 15 Reporting of suspected adverse reactions
Eintrag öffnenKanjinti · 4.8 · All the terms included are based on the highest percentage seen in pivotal clinical studies. In addition, term
Eintrag öffnenKanjinti · 4.8 · Amongst the most serious and/or common adverse reactions reported in trastuzumab usage to date are cardiac dys
Eintrag öffnenKanjinti · 4.8 · Cardiac dysfunction
Eintrag öffnenKanjinti · 4.8 · Congestive heart failure (NYHA class II – IV) is a common adverse reaction associated with the use of trastuzu
Eintrag öffnenKanjinti · 4.8 · Description of selected adverse reactions
Eintrag öffnenKanjinti · 4.8 · Details of risk minimisation measures that are consistent with the EU Risk Management Plan are presented in (s
Eintrag öffnenKanjinti · 4.8 · Febrile neutropenia, leukopenia, anaemia, thrombocytopenia and neutropenia occurred very commonly. The frequen
Eintrag öffnenKanjinti · 4.8 · Haematotoxicity
Eintrag öffnenKanjinti · 4.8 · Immunogenicity
Eintrag öffnenKanjinti · 4.8 · In 3 pivotal clinical studies of adjuvant trastuzumab given in combination with chemotherapy, the incidence of
Eintrag öffnenKanjinti · 4.8 · In the neoadjuvant-adjuvant EBC study (BO22227), at a median follow-up exceeding 70 months, 10.1% (30/296) of
Eintrag öffnenKanjinti · 4.8 · In the pivotal metastatic studies of intravenous trastuzumab, the incidence of cardiac dysfunction varied betw
Eintrag öffnenKanjinti · 4.8 · In this section, the following categories of frequency have been used: very common (≥ 1/10), common (≥ 1/100 t
Eintrag öffnenKanjinti · 4.8 · Infusion reactions, allergic-like reactions and hypersensitivity
Eintrag öffnenKanjinti · 4.8 · It is estimated that approximately 40% of patients who are treated with trastuzumab will experience some form
Eintrag öffnenKanjinti · 4.8 · Presented in Table 1 are adverse reactions that have been reported in association with the use of intravenous
Eintrag öffnen